SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NNVC) (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS ...
The new hires strengthen Inimmune's leadership team and moves the company “toward key milestones and planned expansion into ...
Hospitals and health systems are constantly seeking new ways to improve the quality and cost of care. Increasingly, hospitals and physicians are turning to clinical integration as a strategy to ...
As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results